Merck seeks FDA approval to extend Enflonsia use to at-risk children under 2 in second RSV season

Merck is aiming to expand the use of its RSV preventive treatment Enflonsia to cover children under two at increased risk during their second RSV season, with an FDA decision expected in March 2027, based on promising Phase 3 trial…













